Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




May
05
Today In Oncology
Advanced CKM Syndrome Associated With Greater Cancer Risk
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
Adjuvant Hepatic Arterial Infusion After Surgery for Four or More Colorectal Liver Metastases
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo